You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Litigation Details for ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. (D.N.J. 2020)


✉ Email this page to a colleague

« Back to Dashboard


ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. (D.N.J. 2020)

Docket ⤷  Sign Up Date Filed 2020-04-09
Court District Court, D. New Jersey Date Terminated 2022-01-14
Cause 15:1126 Patent Infringement Assigned To Renee Marie Bumb
Jury Demand None Referred To Sharon A. King
Parties NIPPON SHINYAKU CO., LTD.; ZYDUS WORLDWIDE DMCC
Patents 7,205,302; 8,791,122; 9,284,280
Attorneys ANANDITA VYAKARNAM; GREGORY D. MILLER
Firms Windels Marx Lane & Mittendorf, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC.
The small molecule drug covered by the patents cited in this case is ⤷  Sign Up .

Details for ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. (D.N.J. 2020)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2020-04-09 1 infringement of United States Patent No. 7,205,302 (“the ’302 patent”), United States Patent No. 8,791,122 (“the…the ’122 patent”), and United States Patent No. 9,284,280 (“the ’280 patent”) (collectively, “the patents-in-suit… ’302, ’122, and ’280 patents. THE PATENTS-IN-SUIT … assignee of the patents-in-suit. Actelion is an exclusive licensee of the patents-in-suit. …of the ’302 patent is attached as Exhibit A. 87. The ’122 patent was duly and External link to document
2021-04-28 100 Letter collectively, “Zydus”) as to remaining U.S. Patent No. 7,205,302. If the Stipulation and Proposed…regarding U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”) and defendants…against Alembic with respect to the ’122 patent and the ’280 patent will be voluntarily dismissed, and that…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2021-04-29 101 ~Util - Add and Terminate Parties AND Stipulation and Order expiration of U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”); and …Plaintiffs and Alembic concerning the ’122 and ’280 patents are dismissed without prejudice, and each party…attorney fees with respect to the ’122 and ’280 patents; 2. The case caption should be…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2020-06-04 19 Text of Proposed Order PageID: 277 one or more claims of U.S. Patent Nos. 8,791,122 and 9,284,280 are not invalid and/or unenforceable…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2021-01-25 88 Letter proceed against Zydus as to remaining U.S. Patent No. 7,205,302. These stipulations do not concern…regarding U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”) and certain …collectively, “Zydus”) with respect to the ’122 patent and the ’280 patent will be voluntarily dismissed. The Lawsuit…VGYAAN”), which had involved only the ’122 and ’280 patents, will be voluntarily dismissed from the Lawsuit…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.